सत्याधीशसत्याधीश
SatyaDheesh
India's Ground Truth Record
Pull to refresh
VOL. I · EST. 11.2025 
SatyaDheesh
सत्याधीश
India's Ground Truth Record
LIVE

Karnataka Minister Writes to Union Chief: High-Cost Medicines Sell 70 Times Above Procurement Prices

GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·

Pharmaceutical regulation and price transparency: a GS2 Social Justice and Ethics case study.

Why in news

Karnataka Health Minister U.T. Khader wrote to Union Health Minister J.P. Nadda alleging that high-cost medicines for cancer, kidney ailments, and AIDS are sold at MRPs up to 70 times higher than procurement prices.

Background

The Karnataka government highlighted price discrepancies in life-saving drugs sold by dealers and stockists. The state proposed a national study on price gaps and a cap on patient-facing prices based on acquisition costs plus reasonable margins.

Facts for Prelims

  • FactHigh-cost medicines for cancer, kidney ailments, and AIDS are allegedly sold at MRPs up to 70 times higher than procurement prices.
  • PostU.T. Khader is the Health Minister of Karnataka.
  • PostJ.P. Nadda is the Union Health Minister.

Prelims practice question

Which specific diseases were highlighted by the Karnataka government regarding high-cost medicine price discrepancies?

  1. (a)Malaria and Dengue
  2. (b)Cancer, kidney ailments, and AIDS
  3. (c)Tuberculosis and Typhoid
  4. (d)Diabetes and hypertension
Show answer

Answer: (b) Cancer, kidney ailments, and AIDS — The note specifies that the Karnataka Health Minister highlighted price discrepancies for medicines for cancer, kidney ailments, and AIDS.

For Mains

Q. Discuss the systemic issues in the pharmaceutical supply chain that lead to exorbitant retail prices for life-saving drugs and suggest measures to ensure affordable healthcare.

Dimensions to cover in your answer

  • Market distortion: Lack of price ceilings on essential medicines leads to predatory pricing by intermediaries.
  • Regulatory gap: Inadequate oversight of dealer and stockist margins in the high-cost drug segment.
  • Policy trade-off: Balancing pharmaceutical innovation incentives with the constitutional right to affordable healthcare.

Keywords: Price Ceiling · Supply Chain Transparency · Affordable Healthcare · Market Distortion · Regulatory Oversight

Read the full news →Report a mistake in this noteSource: The Hindu ↗

More Social Justice notes

All Social Justice current affairs →

Something wrong, or something missing?

Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.

Report a mistake →Ask for something →[email protected]

This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.